藥康生物(688046.SH):今年將有北京大興、上海寶山、廣東二期三個設施投產
格隆匯9月6日丨藥康生物(688046.SH)接受特定對象調研 時表示,公司目前價格體系維持良好,上半年沒有進行明顯的價格調整,客户認可公司的交付質量及交付速度,對售前、售中、售後服務滿意度較高,普遍可以接受目前的報價,2023H1 毛利率下滑受價格的影響不大。
2023H1 毛利率下滑主要兩方面原因,一是根據產能規劃,公司今年將有北京大興、上海寶山、廣東二期三個設施投產,其中北京大興設施已於 6 月下旬進入試運營,為順利開啟新設施,公司提前招聘生產人員進行培訓,導致成本增加;二是國內科研客户需求較好,代理繁育、模型定製等業務維持了良好的增速,佔收入比重提升,收入結構變化一定程度影響了毛利率。後續,隨着公司新增產能利用率提升、海外收入佔比的逐步提高,毛利率有望回升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.